Study Number:

Study Gender:

PWG Approval Date:

Version:

PA50: Bone Marrow Smear Summary Test Compound: Black Cohosh CAS Number: 84776-26-1 Date Report Requested: 02/09/2021 Time Report Requested: 08:46:09 Lab: NTP

C00058B-04 Female See web page for date of PWG Approval v1.1.7

PA50: Bone Marrow Smear Summary Test Compound: Black Cohosh CAS Number: 84776-26-1

Date Report Requested: 02/09/2021 Time Report Requested: 08:46:09 Lab: NTP

					Female: 3	B-Month	Interim	Fem								
								Treatmer	nt Group	os (mg/kg))					
	Phase Day		0			30			100			300			1000	
Total Bone Marrow Cell Count (10 ⁷ cells/femur) Percent of Control	SD 92	1.77	± 0.08	(10)	1.91	± 0.08 108.1	(10)	2.02	± 0.07 114.1	(10)	1.95	± 0.06 110.5	(10)	1.86	± 0.07 105.2	(10)
Myeloblast (# cells counted) Percent of Control	SD 92	9.0	± 0.7	(10)	8.3	± 1.4 92.2	(10)	8.9	± 1.1 98.9	(10)	8.0	± 0.6 88.9	(10)	9.6	± 0.9 106.7	(10)
Myelocyte (# cells counted) Percent of Control	SD 92	34.4	± 1.1	(10)	31.2	± 0.8 90.7	(10)	28.0	± 1.0 81.4	(10) **	29.4	± 2.3 85.5	(10)	37.5	± 2.4 109.0	(10)
Promyelocyte (# cells counted) Percent of Control	SD 92	27.3	± 1.4	(10)	23.5	± 1.6 86.1	(10)	24.5	± 1.6 89.7	(10)	23.7	± 2.0 86.8	(10)	28.3	± 1.8 103.7	(10)
Metamyelocyte (# cells counted) Percent of Control	SD 92	52.4	± 2.3	(10)	48.8	± 3.1 93.1	(10)	51.5	± 3.3 98.3	(10)	51.1	± 2.9 97.5	(10)	56.9	± 1.7 108.6	(10)
Band Granulocyte (# cells counted) Percent of Control	SD 92	69.0	± 4.0	(10)	74.1	± 5.5 107.4	(10)	69.6	± 3.0 100.9	(10)	75.4	± 2.8 109.3	(10)	68.5	± 2.2 99.3	(10)
Segmented Granulocyte (# cells counted) Percent of Control	SD 92	151.6	± 5.6	(10)	150.6	± 4.5 99.3	(10)	141.7	± 6.8 93.5	(10)	148.4	± 5.9 97.9	(10)	139.8	± 3.3 92.2	(10)
Rubriblast (# cells counted) Percent of Control	SD 92	9.2	± 1.0	(10)	9.2	± 1.5 100.0	(10)	10.7	± 0.9 116.3	(10)	7.9	± 0.8 85.9	(10)	9.0	± 1.0 97.8	(10)
Rubricyte (# cells counted) Percent of Control	SD 92	43.7	± 3.1	(10)	45.1	± 3.6 103.2	(10)	50.8	± 1.9 116.2	(10)	45.9	± 2.1 105.0	(10)	40.9	± 1.5 93.6	(10)
Prorubricyte (# cells counted) Percent of Control	SD 92	25.2	± 1.9	(10)	26.2	± 2.2 104.0	(10)	30.1	± 1.3 119.4	(10)	26.6	± 1.8 105.6	(10)	26.5	± 1.7 105.2	(10)
Metarubricyte (# cells counted)	SD 92	78.2	± 3.1	(10)	83.1	± 2.5	(10)	84.6	± 4.3	(10)	83.4	± 5.1	(10)	82.9	± 5.8	(10)

Date Report Requested: 02/09/2021 Time Report Requested: 08:46:09 Lab: NTP

Female: 3-Month Interim Fem												
	Treatment Groups (mg/kg)											
	Phase Day	0	30	100	300	1000						
Percent of Control			106.3	108.2	106.6	106.0						
M:E Ratio	SD 92	2.257 ± 0.147 (10)	2.106 ± 0.131 (10)	1.858 ± 0.079 (10)	2.110 ± 0.148 (10)	2.178 ± 0.123 (10)						
Percent of Control			93.3	82.3	93.5	96.5						

PA50: Bone Marrow Smear Summary Test Compound: Black Cohosh CAS Number: 84776-26-1

Date Report Requested: 02/09/2021 Time Report Requested: 08:46:09 Lab: NTP

					Female	: 1-Year	Interim I	Fem								
								Treatment	Groups	s (mg/k	g)					
	Phase Day		0			30			100			300			1000	
Total Bone Marrow Cell Count (10 ⁷ cells/femur) Percent of Control	SD 365	2.14	± 0.07	(10)	2.03	± 0.14 94.7	(10)	2.16	± 0.16 101.1	(10)	2.25	± 0.26 105.2	(10)	2.24	± 0.13 104.8	(10)
Myeloblast (# cells counted) Percent of Control	SD 365	8.0	± 0.8	(10)	8.6	± 0.9 107.5	(10)	5.7	± 0.9 71.3	(10)	6.3	± 0.6 78.8	(10)	6.8	± 0.6 85.0	(10)
Myelocyte (# cells counted) Percent of Control	SD 365	37.3	± 2.2	(10)	45.3	± 1.9 121.4	(10)	42.0	± 2.3 112.6	(10)	34.7	± 1.7 93.0	(10)	35.9	± 2.5 96.2	(10)
Promyelocyte (# cells counted) Percent of Control	SD 365	27.1	± 3.0	(10)	31.1	± 2.4 114.8	(10)	24.3	± 1.9 89.7	(10)	22.5	± 1.7 83.0	(10)	23.1	± 1.3 85.2	(10)
Metamyelocyte (# cells counted) Percent of Control	SD 365	54.6	± 1.6	(10)	58.0	± 2.7 106.2	(10)	65.1	± 3.7 119.2	(10)	58.8	± 3.1 107.7	(10)	61.1	± 2.3 111.9	(10)
Band Granulocyte (# cells counted) Percent of Control	SD 365	64.8	± 2.7	(10)	64.5	± 3.6 99.5	(10)	67.6	± 2.8 104.3	(10)	62.0	± 2.9 95.7	(10)	65.7	± 3.2 101.4	(10)
Segmented Granulocyte (# cells counted) Percent of Control	SD 365	138.2	± 3.3	(10) *	149.2	± 6.9 108.0	(10)	135.0	± 4.8 97.7	(10)	155.4	± 4.3 112.4	(10)	155.4	± 6.1 112.4	(10)
Rubriblast (# cells counted) Percent of Control	SD 365	8.6	± 0.7	(10)	8.9	± 1.0 103.5	(10)	7.5	± 1.0 87.2	(10)	7.8	± 1.0 90.7	(10)	7.8	± 1.2 90.7	(10)
Rubricyte (# cells counted) Percent of Control	SD 365	47.0	± 2.5	(10) *	42.3	± 2.6 90.0	(10)	45.7	± 2.1 97.2	(10)	38.1	± 1.0 81.1	(10) *	42.4	± 3.2 90.2	(10)
Prorubricyte (# cells counted) Percent of Control	SD 365	24.7	± 1.5	(10)	26.9	± 1.4 108.9	(10)	26.4	± 1.2 106.9	(10)	25.0	± 1.9 101.2	(10)	23.7	± 1.7 96.0	(10)
Metarubricyte (# cells counted)	SD 365	89.5	± 2.5	(10)	65.2	± 1.9	(10) **	81.3	± 5.3	(10)	89.4	± 4.3	(10)	78.1	± 4.8	(10)

Study Number: C00058B-04
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

Female: 1-Year Interim Fem													
		Treatment Groups (mg/kg)											
	Phase Day	0	30	100	300	1000							
Percent of Control			72.8	90.8	99.9	87.3							
M:E Ratio	SD 365	1.976 ± 0.108 (10)	2.508 ± 0.085 (10) *	2.164 ± 0.130 (10)	2.162 ± 0.121 (10)	2.396 ± 0.190 (10)							
Percent of Control			126.9	109.5	109.4	121.2							

Date Report Requested: 02/09/2021 Time Report Requested: 08:46:09 Lab: NTP

LEGEND

Data are displayed as mean ± SEM (N) unless otherwise noted.

M:E ratio calculated as the sum of the number of myeloblasts, promyelocytes, myelocytes, metamyelocytes, band granulocytes, and segmented granulocytes divided by the sum of the number of rubriblasts, prorubricytes, rubricytes, and metarubricytes.

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

** END OF REPORT **